PER 0.00% 7.8¢ percheron therapeutics limited

atl1103 anti cancer medications, page-37

  1. 2,315 Posts.
    lightbulb Created with Sketch. 11
    FDA, Food and Drug Administration

    ODA, Orphan Drug Act

    Regulatory harmonization
    In an effort to reduce the burden on manufacturers applying for orphan drug status, the FDA and EMA agreed in late 2007 to utilize a common application process for both agencies. However, the two agencies will continue to maintain separate approval processes.
    In order to encourage the development of drugs for orphan diseases, the ODA included a number of incentives including seven-year market exclusivity for companies that developed orphan drug, tax credits equal to half of the development costs, later changed to a fifteen-year carry-forward provision and a three-year carry-back that can be applied in profitable year, grants for drug development, fast-track approvals of drugs indicated for rare diseases, and expanded access to the Investigational New Drug Program. The law was also later amended to waive user fees charged under.

    ANP are completing ODA which means ATL1103 will fast track approvals and is eligible these said tax rebates on development etc... So we are nearing a free carry stage for ANP once ODA is complete. Phase II takes 18 weeks and 3 is red tape.

    President Ronald Reagan signed the ODA into law. Under the ODA drugs, vaccines, and diagnostic agents would qualify for orphan status if they were intended to treat a disease affecting less than 200,000 American citizens. In order to encourage the development of drugs for orphan diseases, the ODA included a number of incentives including seven-year market exclusivity for companies that developed orphan drug, tax credits equal to half of the development costs, later changed to a fifteen-year carry-forward provision and a three-year carry-back that can be applied in profitable year, grants for drug development, fast-track approvals of drugs indicated for rare diseases, and expanded access to the Investigational New Drug Program. The law was also later amended to waive user fees charged under PDUFA.[1]

    http://en.wikipedia.org/wiki/Orphan_Drug_Act_of_1983


    Blue sky is very close. ANP is a strong buy IMO
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
7.8¢
Change
0.000(0.00%)
Mkt cap ! $70.32M
Open High Low Value Volume
7.8¢ 7.9¢ 7.8¢ $5.891K 75.05K

Buyers (Bids)

No. Vol. Price($)
1 6454 7.7¢
 

Sellers (Offers)

Price($) Vol. No.
7.8¢ 19621 2
View Market Depth
Last trade - 16.10pm 24/07/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.